MFDA Bans Allegra Suspension Syrup Amid Quality Concerns
The Maldives Food and Drug Authority (MFDA) has announced a ban on the anti-allergic medicine Allegra suspension syrup (fexofenadine hydrochloride) following concerns over quality issues.
In a statement released today, the MFDA reported that the decision came after the pharmaceutical company Sanofi India, the producer of the drug, alerted the authority to quality problems in three batches of the Allegra suspension syrup imported into the Maldives. The affected batches are AL1223019, AL1223029, and AL1223060.
advertisement
pic.twitter.com/3YuTiN6Aoa— MFDA (@MFDA_mv) August 4, 2024
The MFDA has requested that pharmacies, warehouses, and medical care facilities currently in possession of the specified batches of Allegra suspension syrup notify the authority via email at mtg@health.gov.mv. For additional information, individuals are advised to contact the MFDA’s hotline at 7200321.
Allegra suspension syrup is commonly administered to children to alleviate symptoms associated with allergic conditions such as fever, watery eyes, runny nose, sneezing, itching, and the common cold.
